SURTAVI: TAVR Matches Surgery in Lowest-Risk Cohort

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — Using the CoreValve and Evolut R devices, transcatheter aortic valve replacement (TAVR) was deemed non-inferior to surgery in the lowest-risk randomized dataset yet, according to the SURTAVI trial presented here — but the story is not that simple. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session

< Back to Listings